Sales and EBITDA grew in H1 2025, led by Specialty Chemicals, especially creatine and custom synthesis. CapEx and customer grants support major expansions, while risks include energy costs, Chinese competition, and regulatory uncertainty. Guidance for 2025 is confirmed.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.